Intravenous amiodarone
PR Kowey,
RA Marinchak,
SJ Rials,
and
RA Filart
Division of Cardiovascular Diseases, Lankenau Hospital and Medical Research Center, Wynnewood, Pennsylvania 19096, USA.
Intravenous amiodarone was approved in 1995 for the treatment of malignant and resistant ventricular arrhythmia. Although it is an "old drug," much has been learned recently about this complex drug and its application in a variety of cardiac arrhythmias. The objectives of this review were to summarize what is known about intravenous amiodarone, including its pharmacologic and electrophysiologic effects, to review its efficacy for the treatment of patients with highly malignant ventricular arrhythmia and to provide specific information about its clinical use for this and other indications. The studies that were reviewed were selected on the basis of time published (from 1983 to 1995) and the completeness of information provided regarding patient clinical characteristics, drug dosing and methods of evaluation, efficacy analyses, long-term follow-up and complications. The full data from the three controlled trials that formed the basis of the drug's approval are contained in published reports that were also extensively reviewed. Intravenous amiodarone has demonstrable efficacy for the treatment of frequently recurrent destabilizing ventricular tachycardia and ventricular fibrillation, with suppression rates of 63% to 91% in uncontrolled trials. The three pivotal trials confirmed these findings and demonstrated a dose-response relation, with at least comparable efficacy to bretylium, a drug with a similar indication. The safety profile has also been well described; cardiovascular adverse effects are the most frequent, especially hypotension. Intravenous amiodarone is a useful addition to the drugs available for the treatment of patients with very severe ventricular arrhythmia. Its use in patients with other rhythm disorders appears promising, but final recommendations must await development of definitive data from ongoing clinical trials.
This article has been cited by other articles:
|
|
|
|
 
American College of Cardiology Foundation, American Heart Association Task Force on Practice, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interve, Society for Vascular Medicine, Society for Vascular Surgery, L. A. Fleisher, et al.
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
J. Am. Coll. Cardiol.,
November 24, 2009;
54(22):
e13 - e118.
[Full Text]
[PDF]
|
|
|
|
|
|
|
2007 WRITING COMMITTEE MEMBERS, L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. L. Chaikof, K. E. Fleischmann, W. K. Freeman, J. B. Froehlich, E. K. Kasper, et al.
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
November 24, 2009;
120(21):
e169 - e276.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Cushing, M. P. Adams, W. D. Cooper, P. R. Kowey, and R. J. Lipicky
Bioequivalence of 2 Intravenous Amiodarone Formulations in Healthy Participants
J. Clin. Pharmacol.,
April 1, 2009;
49(4):
407 - 415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. L. Chaikof, K. E. Fleischmann, W. K. Freeman, J. B. Froehlich, E. K. Kasper, J. R. Kersten, et al.
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
e159 - e242.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. L. Chaikof, K. E. Fleischmann, W. K. Freeman, J. B. Froehlich, E. K. Kasper, J. R. Kersten, et al.
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery)
Circulation,
October 23, 2007;
116(17):
e418 - e500.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol.,
September 5, 2006;
48(5):
e247 - e346.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
746 - 837.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Saul, W. A. Scott, S. Brown, P. Marantz, V. Acevedo, S. P. Etheridge, J. C. Perry, J. K. Triedman, S. W. Burriss, P. Cargo, et al.
Intravenous Amiodarone for Incessant Tachyarrhythmias in Children: A Randomized, Double-Blind, Antiarrhythmic Drug Trial
Circulation,
November 29, 2005;
112(22):
3470 - 3477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Yeung-Lai-Wah, A. Qi, E. McNeill, J. G. Abel, S. Tung, K. H. Humphries, and C. R. Kerr
New-onset sustained ventricular tachycardia and fibrillation early after cardiac operations
Ann. Thorac. Surg.,
June 1, 2004;
77(6):
2083 - 2088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yagdi, S. Nalbantgil, F. Ayik, A. Apaydin, F. Islamoglu, H. Posacioglu, T. Calkavur, Y. Atay, and S. Buket
Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting
J. Thorac. Cardiovasc. Surg.,
June 1, 2003;
125(6):
1420 - 1425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Chevalier, A. Durand-Dubief, H. Burri, M. Cucherat, G. Kirkorian, and P. Touboul
Amiodarone versus placebo and class ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis
J. Am. Coll. Cardiol.,
January 15, 2003;
41(2):
255 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Silfvast, V. Pettila, K. A. Ballew, J. T. Philbrick, W. Tomkiewicz, D. G. Meininghaus, K. Langes, J. Spehn, P. Dorian, B. Schwartz, et al.
Amiodarone versus Lidocaine for Shock-Resistant Ventricular Fibrillation
N. Engl. J. Med.,
August 1, 2002;
347(5):
368 - 370.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. J. Dias Da Silva, T. Gnecchi-Ruscone, B. Lavelli, V. Bellina, D. Manzella, A. Porta, A. Malliani, and N. Montano
Opposite effects of iv amiodarone on cardiovascular vagal and sympathetic efferent activities in rats
Am J Physiol Regulatory Integrative Comp Physiol,
August 1, 2002;
283(2):
R543 - R548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kulakowski, S. Karczmarewicz, G. Karpinski, M. Soszynska, and L. CeremuzYnski
Effects of intravenous amiodarone on ventricular refractoriness, intraventricular conduction, and ventricular tachycardia induction
Europace,
January 1, 2000;
2(3):
207 - 215.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. H. Kulier, E. Novalija, Q. Hogan, M. N. Vicenzi, H. J. Woehlck, J. Bajic, J. L. Atlee III, and Z. J. Bosnjak
The Effects of the New Antiarrhythmic E 047/1 on Postoperative Ischemia-Induced Arrhythmias in Dogs
Anesth. Analg.,
December 1, 1999;
89(6):
1393 - 1393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Fuhua Chen, S. Naim, W. F. Friedman, T. S. Klitzner, and G. T. Wetzel
Age-Dependent Changes in the Effects of Amiodarone on Rabbit Cardiac Myocyte Contractions
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 1999;
4(1):
23 - 32.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C.-T. Tai, S.-A. Chen, A.-N. Feng, W.-C. Yu, Y.-J. Chen, and M.-S. Chang
Electropharmacologic Effects of Class I and Class III Antiarrhythmia Drugs on Typical Atrial Flutter : Insights Into the Mechanism of Termination
Circulation,
May 19, 1998;
97(19):
1935 - 1945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
